The little pink pill is coming. In 2014, FDA identified HSDD as one of 20 disease areas of high priority. Given the FDA focus and the promise of a multibillion market, there is little doubt that the treatment for HSDD will become a reality soon. Until it happens, however, the only way to access the promising medications is by participating in clinical trials.